{"nctId":"NCT00338962","briefTitle":"Naltrexone & SSRI in Alcoholics With Depression/PTSD","startDateStruct":{"date":"2001-10"},"conditions":["Alcoholism","Depression","PTSD"],"count":88,"armGroups":[{"label":"Paroxetine and naltrexone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: paroxetine","Drug: Naltrexone"]},{"label":"paroxetine and placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: paroxetine","Drug: Placebo"]},{"label":"Desipramine and naltrexone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: desipramine","Drug: Naltrexone"]},{"label":"Desipramine and placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: desipramine","Drug: Placebo"]}],"interventions":[{"name":"paroxetine","otherNames":["paxil"]},{"name":"desipramine","otherNames":["Norpramin"]},{"name":"Naltrexone","otherNames":["Vivitrol"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* DSM-IV diagnosis of alcohol dependence and current DSM-IV depressive disorder or PTSD\n* a recent episode of heavy drinking\n* outpatient, sober from alcohol and other abused substance for at least 2 days before randomization\n* stable medication regiment for at least 2 weeks\n* women on adequate methods of contraception\n\nExclusion Criteria:\n\n* current opioid dependence or abuse\n* history (within the last 3 months) of opioid dependence or abuse\n* pregnant\n* history of psychotic disorders or current treatment with antipsychotic medications\n* medication thought to influence drinking including: acamprosate, disulfiram, naltrexone, ondansetron, valproic acid or tegretol\n* current (within the lst 6 months) use of MAO inhibitors\n* suicidal active ideation or intent\n* significant underlying medical condition\n* history of cardiac condition abnormalities","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Self-report Weekly Craving Via Obsessive Compulsive Drinking Scale (OCDS)","description":"The OCDS is a 14-item (rated 0-4), self-administered questionnaire for characterizing and quantifying the obsessive and compulsive cognitive aspects of craving and heavy (alcoholic) drinking, such as drinking-related thought, urges to drink, and the ability to resist those thoughts and urges. A higher total score indicates higher craving and ranges from 0-48.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.273","spread":"2.547"},{"groupId":"OG001","value":"20.700","spread":"2.672"},{"groupId":"OG002","value":"18.500","spread":"2.547"},{"groupId":"OG003","value":"21.458","spread":"2.439"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.013","spread":"3.009"},{"groupId":"OG001","value":"9.690","spread":"3.025"},{"groupId":"OG002","value":"4.296","spread":"2.847"},{"groupId":"OG003","value":"7.489","spread":"2.483"}]}]}]},{"type":"PRIMARY","title":"Clinician-Administered PTSD Scale (CAPS)","description":"The CAPS is the gold standard in PTSD assessment. The CAPS-5 is a 30-item structured interview that can be used to:\n\nMake current (past month) diagnosis of PTSD Make lifetime diagnosis of PTSD Assess PTSD symptoms over the past week Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). A higher score is associated with higher severity of PTSD. The score is interpreted as follows: 0-19=Asymptomatic/few symptoms 20-39=Sub-threshold/mild PTSD 40-59=Threshold PTSD/moderate 60-79=Severe PTSD \\>80=Extreme PTSD","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.54","spread":"5.007"},{"groupId":"OG001","value":"69.810","spread":"5.166"},{"groupId":"OG002","value":"62.500","spread":"5.047"},{"groupId":"OG003","value":"77.833","spread":"4.832"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.024","spread":"5.53"},{"groupId":"OG001","value":"36.591","spread":"5.570"},{"groupId":"OG002","value":"26.751","spread":"5.353"},{"groupId":"OG003","value":"41.392","spread":"4.949"}]}]}]},{"type":"PRIMARY","title":"Hamilton Depression Rating Scale (HAM-D)","description":"The HAM-D ranges from 0 (Normal) to \\>23 (Very Severe Depression)","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.273","spread":"1.112"},{"groupId":"OG001","value":"10.950","spread":"1.167"},{"groupId":"OG002","value":"11.195","spread":"1.132"},{"groupId":"OG003","value":"13.167","spread":"1.065"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.328","spread":"1.256"},{"groupId":"OG001","value":"8.238","spread":"1.299"},{"groupId":"OG002","value":"8.563","spread":"1.201"},{"groupId":"OG003","value":"8.943","spread":"1.117"}]}]}]},{"type":"PRIMARY","title":"Mean Number of Side Effects","description":"Differences in mean number of side effects reported for each group. Side effects and common adverse symptoms were evaluated by the research staff weekly, using a modified version of the ystematic Assessment for Treatment Emergent Events. The symptoms that are known to be associated with treatment with desipramine, paroxetine, and naltrexone were specifically screened or on a weekly basis. The symptoms were then clustered into the following categories: gastrointestinal, emotional, cold and flu symptoms, skin, sexual, neurological, and cardiac.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.651","spread":".487"},{"groupId":"OG001","value":"2.688","spread":".513"},{"groupId":"OG002","value":"3.052","spread":".475"},{"groupId":"OG003","value":"3.653","spread":".431"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.874","spread":".686"},{"groupId":"OG001","value":"3.963","spread":".719"},{"groupId":"OG002","value":"3.727","spread":".689"},{"groupId":"OG003","value":"5.248","spread":".629"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.212","spread":"1.058"},{"groupId":"OG001","value":"5.078","spread":"1.106"},{"groupId":"OG002","value":"4.201","spread":"1.047"},{"groupId":"OG003","value":"4.566","spread":".970"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.182","spread":".490"},{"groupId":"OG001","value":"2.393","spread":".512"},{"groupId":"OG002","value":"1.891","spread":".483"},{"groupId":"OG003","value":"2.253","spread":".447"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.002","spread":".240"},{"groupId":"OG001","value":".859","spread":".252"},{"groupId":"OG002","value":".591","spread":".236"},{"groupId":"OG003","value":"1.057","spread":".215"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".877","spread":".241"},{"groupId":"OG001","value":".932","spread":".252"},{"groupId":"OG002","value":".737","spread":".238"},{"groupId":"OG003","value":".736","spread":".219"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".416","spread":".093"},{"groupId":"OG001","value":".474","spread":".101"},{"groupId":"OG002","value":".389","spread":".089"},{"groupId":"OG003","value":".356","spread":".076"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":22},"commonTop":["Dizziness and Lightheadedness","Incarcerated for intoxication","Tachycardia","Suicidal Ideation"]}}}